Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (71-80 of 442) with videos related to

Pageof 45
Sort By:
American Journal of Hematology|January 5, 2017
Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMTJonathan Canaani, Eric Beohou, Myriam Labopin, et al.
Blood|September 3, 2017
Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 studyFlorent Malard, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
Blood|June 28, 2003
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrowNorbert C Gorin, Myriam Labopin, Vanderson Rocha, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|September 28, 2020
Nutritional support in stem cell transplantation programs: Results from a multicenter survey of nurses on behalf of the Nurses Group and Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation and the Gruppo Italiano Trapianto di Midollo OsseoStefano Botti, Steffie van der Werf, Jacqui Stringer, et al.
Leukemia Research|June 25, 2014
Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institutionPierre Hirsch, Myriam Labopin, Frank Viguié, et al.
Haematologica|September 24, 2009
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune DiseasesDominique Farge, Myriam Labopin, Alan Tyndall, et al.
Haematologica|October 1, 2016
Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSebastian Giebel, Myriam Labopin, Gerard Socié, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2006
Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow TransplantationNorbert-Claude Gorin, Myriam Labopin, Jean-Michel Boiron, et al.
Blood Advances|April 10, 2024
Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMTArnon Nagler, Myriam Labopin, Johanna Tischer, et al.
Blood Cancer Journal|November 20, 2019
Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMTAvichai Shimoni, Myriam Labopin, Jürgen Finke, et al.
Pageof 45

Showing results (71-80 of 442) with videos related to

Sort By:
Pageof 45
American Journal of Hematology|January 5, 2017
Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMTJonathan Canaani, Eric Beohou, Myriam Labopin, et al.
Blood|September 3, 2017
Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 studyFlorent Malard, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
Blood|June 28, 2003
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrowNorbert C Gorin, Myriam Labopin, Vanderson Rocha, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|September 28, 2020
Nutritional support in stem cell transplantation programs: Results from a multicenter survey of nurses on behalf of the Nurses Group and Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation and the Gruppo Italiano Trapianto di Midollo OsseoStefano Botti, Steffie van der Werf, Jacqui Stringer, et al.
Leukemia Research|June 25, 2014
Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institutionPierre Hirsch, Myriam Labopin, Frank Viguié, et al.
Haematologica|September 24, 2009
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune DiseasesDominique Farge, Myriam Labopin, Alan Tyndall, et al.
Haematologica|October 1, 2016
Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSebastian Giebel, Myriam Labopin, Gerard Socié, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2006
Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow TransplantationNorbert-Claude Gorin, Myriam Labopin, Jean-Michel Boiron, et al.
Blood Advances|April 10, 2024
Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMTArnon Nagler, Myriam Labopin, Johanna Tischer, et al.
Blood Cancer Journal|November 20, 2019
Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMTAvichai Shimoni, Myriam Labopin, Jürgen Finke, et al.
Pageof 45